目的 探讨金水宝片联合吸入用复方异丙托溴铵溶液治疗慢性阻塞性肺疾病的疗效。方法 收集2022年2月—2024年1月就诊宜兴市人民医院的79例慢性阻塞性肺疾病患者资料，按随机数字表法将患者分为对照组（40例）和治疗组（39例）。对照组使用吸入用复方异丙托溴铵溶液，2喷/次，4次/d。治疗组在对照组基础上口服金水宝片，4片/次，3次/d。治疗2周后统计治疗效果。对比两组的治疗效果、症状缓解时间、病情程度、肺功能指标和血清指标水平。结果 治疗组的总有效率为94.87%，对照组的总有效率为80.00%，组间的比较差异有统计学意义（P＜0.05）。治疗组患者喘息、胸闷、肺啰音、咯痰缓解时间均短于对照组（P＜0.05）。治疗后，两组的慢性阻塞性肺病评估测试（CAT）评分均显著降低（P＜0.05），且治疗组CAT评分较对照组更低（P＜0.05）。治疗后，两组用力肺活量（FVC）/第一秒用力呼气容积（FEV₁）、最大通气量（MVV）、呼气峰值流量（PEF）均显著升高（P＜0.05），且治疗组FVC/FEV₁、MVV、PEF较对照组更高（P＜0.05）。治疗后，两组的血清Clara细胞分泌蛋白-16（CC-16）、白细胞介素-17A（IL-17A）、基质金属蛋白酶-9（MMP-9）水平显著降低（P＜0.05）；治疗组的血清CC-16、IL-17A、MMP-9水平低于对照组（P＜0.05）。结论 金水宝片联合吸入用复方异丙托溴铵溶液可提高慢性阻塞性肺疾病的临床疗效，改善临床症状和肺功能，控制病情发展，减轻炎症反应。

Objective To investigate the efficacy of Jinshuibao Tablets combined with Compound Ipratropium Bromide Solution for inhalation in treatment of chronic obstructive pulmonary disease. Methods 79 Patients with chronic obstructive pulmonary disease who visited Yixing People’s Hospital from February 2022 to January 2024, and divide them into a control group (40 cases) and a treatment group (39 cases) using a random number table method. Patients in control group received Compound Ipratropium Bromide Solution for inhalation, 2 sprays/time, 4 times daily. Patients in the treatment group was given Jinshui Bao Tablets orally on the basis of control group, 4 tablets/time, 3 times daily. Patients in both groups were evaluated after 2 weeks of treatment. The therapeutic effect, symptom remission time, disease degree, lung function index, and serum index were compared between two groups. Results The total effective rate of the treatment group (94.87%) was higher than that of the control group (80.00%), and there was a significant difference between the groups (P < 0.05). The relief time of wheezing, chest tightness, pulmonary rales, and sputum in the treatment group was lower than that in the control group (P < 0.05). After treatment, CAT scores in both groups were lower than those before treatment, and CAT score of the treatment group was lower than that of the control group (P < 0.05). After treatment, FVC/FEV₁, MVV, and PEF of both groups were higher than those before treatment (P < 0.05), and FVC/FEV₁, MVV, and PEF of the treatment group was higher than those of the control group (P < 0.05). After treatment, the serum levels of CC-16, IL-17A, and MMP-9 were significantly decreased in both groups (P < 0.05). The serum levels of CC-16, IL-17A, and MMP-9 in the treatment group were lower than those in the control group after treatment (P < 0.05). Conclusion Jinshuibao Tablets combined with Compound Ipratropium Bromide Solution for inhalation can improve the efficacy of COPD, enhance symptom improvement efficiency, control disease progression, improve lung function, alleviate inflammatory reactions.

R974

无锡市卫生健康委科研项目(Z202220)